

Supplementary Table 1 Baseline characteristics of the included and excluded patients.

Variable	Excluded patients	Included patients	<i>p</i> value
Total (n and %)	56	9	
Age (years)	85.2 ± 4.1	78.5 ± 9.4	0.042
BMI (kg/m²)	30.5 ± 5.4	29.4 ± 5.7	0.581
Weight (kg)	75.8 (71.5 – 87.5)	78.9 (66.2 – 87.1)	0.895
SBP at admission (mmHg)	135.1 ± 15.7	134.9 ± 21.8	0.925
DBP at admission (mmHg)	75.1 ± 15.0	76.9 ± 13.6	0.717
HR (b/min)	86.7 ± 17.5	79.7 ± 16.2	0.236
NYHA (n and %)			0.863
• I	1 (11.1)	10 (17.9)	
• II	5 (55.6)	30 (53.6)	
• III	3 (33.3)	14 (24.0)	
• IV	0 (0.0)	2 (3.6)	
HF treatment (n and %)			
• ACEI/ARB-II	5 (55.6)	39 (69.6)	0.402
• β-blockers	3 (33.3)	34 (60.7)	0.124
• MRA	0 (0.0)	16 (28.6)	0.065
• Loop diuretic	5 (55.6)	43 (76.8)	0.179
• Antiplatelet drugs	3 (33.3)	17 (30.4)	0.857
• Anticoagulant treatment	6 (66.7)	35 (62.0)	0.804
History (n and%)			
• Admission due to HF	4 (44.4)	37 (66.1)	0.212
• Hypertension	6 (66.7)	47 (83.9)	0.215
• Dyslipidaemia	3 (33.3)	33 (58.9)	0.152
• Ischaemic C.	2 (22.2)	17 (30.4)	0.618
• Diabetes	2 (22.2)	25 (44.6)	0.205
• Atrial fibrillation/flutter	8 (88.9)	35 (62.5)	0.120
• COPD/asthma	1 (11.1)	8 (14.3)	0.798
• Chronic kidney failure	2 (22.2)	19 (33.9)	0.486
• Coronary intervention	2 (22.2)	21 (37.5)	0.374
• Pacemaker	0 (0.0)	7 (12.5)	0.262

ACEI: angiotensin-converting enzyme inhibitor; ARB-II: angiotensin II receptor blockers; BMI: body mass index; COPD: chronic obstructive pulmonary disease; DBP: diastolic blood pressure; HF: heart failure; HR: heart rate; Ischaemic C.: ischaemic heart disease; MRA: mineralocorticoid receptor antagonist; NYHA: New York Heart Association; SBP: systolic blood pressure.

Supplementary Table 2 Clinical and analytical characteristics of the included and excluded patients.

Variable	Excluded patients	Included patients	<i>p</i> value
Ultrasound variables			
IVC diameter (mm)	21.4 ± 3.7	21.4 ± 6.7	0.992
IVC collapse (%)	42.9 ± 26.7	36.5 ± 25.4	0.514
Clinical variables			
Average stay (days)	7 (5 – 11)	8 (6 – 10)	0.535
PIA (mmHg)	14 (13.5 – 21.5)	15.0 (11.0 – 17.2)	0.555
Urea (g/dL)	0.58 (0.40 – 0.68)	0.57 (0.40 – 0.83)	0.812
Creatinine (mg/dL)	0.84 (0.72 – 1.22)	1.10 (0.89 – 1.44)	0.120
Glomerular filtration (mL/min/1.72 m ²)	60.6 ± 17.7	55.8 ± 21.5	0.531
Uric acid (mg/dL)	7.48 ± 2.0	7.66 ± 2.6	0.989
Total proteins (mg/dL)	6.2 ± 0.4	6.5 ± 0.7	0.316
Total cholesterol (mg/dL)	128.8 ± 19.1	138.5 ± 32.7	0.457
Triglycerides (mg/dL)	101 (74 – 131)	87 (67 – 107)	0.298
Albumin (mg/dL)	2.8 ± 0.4	3.1 ± 0.3	0.036
Sodium (mEq/L)	141.8 ± 2.3	140.4 ± 4.7	0.494
Potassium (mEq/L)	3.6 ± 0.4	4.2 ± 0.5	0.007
Chlorine (mEq/L)	96.4 ± 4.0	98.6 ± 5.1	0.334
Bicarbonate (mmol/L)	29.7 (25.1 – 31.5)	25.1 (22.3 – 27.9)	0.088
Hemoglobin (g/L)	11.0 ± 2.0	11.9 ± 1.5	0.139
Hematocrit (%)	33.8 ± 5.5	36.8 ± 4.2	0.061
Biomarkers			
NT-proBNP (pg/mL)	3419 (2377 – 13862)	3607 (2208 – 7389)	0.735
Cystatin (mg/dL)	1.23 (0.75 – 1.88)	1.46 (1.14 – 1.80)	0.717
CA125 (U/mL)	35.1 (19.7 – 62.0)	43.6 (17.3 – 103.6)	0.588
Impedance audiometry			
TBW (L)	37.7 (35.2 – 38.3)	42.4 (35.6 – 47.9)	0.149
EVF (L)	25.9 (20.0 – 29.8)	23.1 (18.1 – 29.2)	0.610

CA125: carbohydrate antigen 125; EVF: total extracellular fluid volume; IVC: inferior vena cava; NT-proBNP: N-terminal pro b-type natriuretic peptide; PIA: intraabdominal pressure; TBW: total body water volume.

Supplementary Table 3 Analysis of congestion according to the median diuretic response during the first 72 hours (mmol Na/mg furosemide i.v.).

Variable	DR < media	DR > media	p value
Ultrasound variables			
IVC diameter at 72 hours (mm)	19.4 (12.8 – 23.6)	17.2 (15.5 – 21.1)	0.021
IVC diameter at discharge (mm)	17.0 (14.1 – 24.0)	16.0 (13.7 – 18.8)	0.858
IVC collapse at 72 hours (%)	40.7 (17.3 – 66.4)	50.0 (41.7 – 65.3)	0.023
IVC collapse at discharge (%)	38.2 (16.5 – 60.4)	54.1 (38.3 – 90.4)	0.266
Biomarkers			
NT-proBNP at discharge (pg/mL)	2245 (988 – 3200)	1988 (650 – 3799)	0.265
CA125 at discharge (U/mL)	53.8 (24.7 – 170.7)	38.7 (16.6 – 57.8)	0.212
Impedance audiometry			
TBW at 72 hours (L)	42.5 (41.0 – 50.3)	36.5 (33.0 – 45.4)	0.002
TBW at discharge (L)	27.8 (22.5 – 32.6)	19.5 (16.0 – 25.8)	0.009
EVF at 72 hours (L)	39.5 (35.5 – 48.9)	38.3 (32.2 – 43.5)	0.205
EVF at discharge (L)	26.0 (18.7 – 31.4)	20.7 (16.7 – 30.4)	0.131
Objectives per year (n and%)			
All-cause death	8 (29.6)	6 (42.9)	0.589
Readmission for HF	17 (58.6)	14 (50.0)	0.514
Combined endpoint of death and/or readmission for HF	17 (58.6)	14 (50.0)	0.514

CA125: carbohydrate antigen 125; DR: diuretic response; EVF: total extracellular fluid volume; HF: heart failure; IVC: inferior vena cava; NT-proBNP: N-terminal pro b-type natriuretic peptide; PIA: intraabdominal pressure; TBW: total body water volume.